SREBP-mediated Signaling Restores Stem Cell Niche Properties in Human Lung Fibroblasts.
Justeau G., Toigo M., Ribeiro Baptista B., Herath D., Yilmaz R., Crépin L.
Prospective Study, published in Am J Respir Cell Mol Biol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Am J Respir Cell Mol Biol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40920982
- DOI
- 10.1165/rcmb.2024-0541OC
Abstract (original English)
Emphysema is characterized by chronic alveolar destruction. Lipofibroblasts (LIFs) are crucial in the stem cell niche surrounding alveolar type II cells and may contribute to alveolar regeneration. We aim to determine whether emphysema is associated with LIF reduction and whether SREBP (sterol regulatory element-binding protein) activation promotes LIF differentiation and fibroblast stem cell niche properties. We quantified LIFs in the lungs of patients with emphysema compared with controls by costaining vimentin and ADFP (adipose differentiation-related protein). Using available datasets, we explored the expression level of lipogenic pathways in mesenchymal cells. Fibroblasts from patients were isolated, and SREBP-mediated signaling was activated with an LXR (liver X receptor) agonist, T0901317, and compared with rosiglitazone, a PPAR-γ (peroxisome proliferator-activated receptor γ) agonist (gene expression and lipidomic analysis). The stem cell niche properties of fibroblasts were evaluated through coculture with the H441 cell line or primary alveolar type II cells in organoid assays. Patients with emphysema had half as many LIFs as controls. T0901317 induced lipogenic differentiation of human lung fibroblasts and increased triglyceride contents and several phosphatidylcholine forms, particularly dipalmitoylphosphatidylcholine (PC32_0), one of the main surfactant components.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.